Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+1.77%
$149.47
100% positive prob.
5-Day Prediction
+2.57%
$150.64
100% positive prob.
20-Day Prediction
-0.01%
$146.86
95% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | BUY | +1.77% | +2.57% | -0.01% | 100.0% | Pending |
| Q2 2026 | SELL | -1.29% | -2.21% | +0.83% | 100.0% | Pending |
| Q1 2026 | BUY | +1.52% | +2.68% | +1.35% | 100.0% | +2.66% |
| Q4 2025 | BUY | +1.06% | +2.48% | +2.75% | 100.0% | +3.88% |
SEC 8-K filings with transcript text
Nov 3, 2026 · 100% conf.
1D
+1.77%
$149.47
Act: -1.80%
5D
+2.57%
$150.64
20D
-0.01%
$146.86
2 exhibit991enrschedules-3q26.htm
Document
Exhibit 99.1
DuPont Reports Third Quarter 2026 Results
Exceeds Third Quarter 2026 Guidance
Raises Full Year 2026 Guidance
Third Quarter 2026 Highlights
•Net Sales of $1.9 billion increased 4%; organic sales increased 5% versus year-ago period
•GAAP Income from continuing operations of $171 million; operating EBITDA of $469 million
• GAAP EPS from continuing operations of $1.24; adjusted EPS of $2.09
• Cash provided by operating activities from continuing operations of $410 million; transaction-adjusted free cash flow of $341 million representing 121% conversion
• Completed $250 million accelerated share purchase and substantially completed $100 million of open market share repurchases in the third quarter
• Announces intent to repurchase $250 million of shares in the fourth quarter
WILMINGTON, Del., Nov. 3, 2026 - DuPont (NYSE: DD) announced its financial results(1) for the third quarter ended September 30, 2026 and again raised financial guidance for the full year 2026.
“We delivered another quarter of consistent, high-quality performance, once again exceeding our financial guidance,” said Lori Koch, DuPont Chief Executive Officer. “Mid-single-digit organic growth, strong operating leverage and disciplined capital allocation drove significant adjusted EPS growth. Additionally, we delivered strong free cash flow performance, with 121% conversion, underscoring the quality of our earnings and effective execution.
“We are executing from a position of strength and remain focused on unlocking the full potential of our portfolio to deliver sustained long-term value creation,” Koch concluded.
Third Quarter 2026 Consolidated Results(1)
Dollars in millions, except EPS
Change
vs. 3Q’25
Organic Sales (2)
vs. 3Q’25
Net sales$1,868$1,7954%5%
GAAP Income from continuing operations$171$10268%
Operating EBITDA(2) $469$4368%
Operating EBITDA margin(2) % 25.1%24.3%80 bps
GAAP EPS from continuing operations$1.24$0.7077%
Adjusted EPS(2) $2.09$1.2962%
Cash provided by operating activities – cont. ops.$410$32227%
Transaction-adjusted free cash flow(2)
$341$346(1%)
(1)Results and cash flows are presented on a continuing operations basis. See page 6 for further information, including the basis of presentation included in this release.
(2)Organic sales, operating EBITDA, operating EBITDA margin, adjusted EPS, transaction-adjusted free cash flow and transaction-adjusted free cash flow conversion are non-GAAP measures and only reflect continuing operations. See page 6 for further discussion, including a definition of significant items. Reconciliation to the most directly comparable GAAP measure, including details of significant items begins on page 13 of this communication.
Net sales
•Net sales were up 4% on a 5% increase in organic sales partially offset by a 1% headwind from currency.
• 4% organic sales growth in Healthcare & Water Technologies; 5% organic sales growth in Diversified Industrials.
GAAP Income from continuing operations
•GAAP Income/GAAP EPS from continuing operations improved on higher segment earnings and lower interest expense and transaction costs.
Operating EBITDA
•Operating EBITDA increased on organic growth and productivity.
Adjusted EPS
•Adjusted EPS increased on higher segment earnings and lower net interest expense, tax rate, and share count.
Cash provided by operating activities from continuing operations
•Cash provided by operating activities from continuing operations in the quarter of $410 million, capital expenditures of $71 million, and separation-related transaction costs and other payments of $2 million resulted in transaction-adjusted free cash flow and related conversion of $341 million and 121%, respectively.
Third Quarter 2026 Segment Highlights
Healthcare & Water Technologies
Dollars in millions
Change
vs. 3Q’25
Organic Sales(2)
vs. 3Q’25
Net sales$865$8324%4%
Operating EBITDA$263$2467%
Operating EBITDA margin %30.4%29.6%80 bps
Net sales
•Net sales increased 4% on organic sales growth in the quarter. Third quarter 2025 net sales included a benefit of $15 million, or 2%, from the order timing shift from the fourth quarter 2025 due to separation-related activities, primarily in Water Technologies.
◦Healthcare Technologies sales up mid-single digits on an organic basis led by growth in personal protection and medical packaging.
◦Water Technologies sales up low-single digits on an organic basis on strength in industrial water, semiconductor and specialty markets, partially offset by continued disruptions in the Middle East.
Operating EBITDA
•Operating EBITDA and margin increased on organic growth and productivity.
2
Diversified Industrials
Dollars in millions
3Q’25Change vs. 3Q’25 Organic Sales(2)
vs. 3Q’25
Net sales$1,003$9634%5%
Operating EBITDA$242$21911%
Operating EBITDA margin %24.1%22.7%140 bps
Net sales
•Net sales increased 4
Aug 4, 2026 · 100% conf.
1D
-1.29%
$140.66
Act: +3.31%
5D
-2.21%
$139.35
20D
+0.83%
$143.68
2 exhibit991enrschedules-2q26.htm
Document
Exhibit 99.1
DuPont Reports Second Quarter 2026 Results
Exceeds Second Quarter 2026 Guidance
Raises Full Year 2026 Guidance
Second Quarter 2026 Highlights
•Net Sales of $1.8 billion increased 4%; organic sales increased 4% versus year-ago period
•GAAP Income from continuing operations of $191 million; operating EBITDA of $448 million
• GAAP EPS from continuing operations of $1.37; adjusted EPS of $1.88
• Cash provided by operating activities from continuing operations of $400 million; transaction-adjusted free cash flow of $326 million representing 127% conversion
• Announces intent to repurchase $250 million of shares in the third quarter
• Announces the Company’s Global Industry Classification Standard (GICS) code has changed to Industrials effective July 31, 2026
WILMINGTON, Del., Aug. 4, 2026 - DuPont (NYSE: DD) announced its financial results(1) for the second quarter ended June 30, 2026 and raised financial guidance for the full year 2026.
“We delivered another strong quarter, exceeding our financial guidance and demonstrating our focus on consistent execution” said Lori Koch, DuPont Chief Executive Officer. “Mid-single digit organic growth, strong margin expansion, coupled with robust adjusted EPS growth and free cash flow generation underscore the strength of our market-leading businesses and reflect disciplined execution of our strategic priorities, supported by our ongoing focus on excellence and productivity.”
“We are delivering on our commitments, creating value for all of our key stakeholders and further strengthening the foundation for sustainable, long-term profitable growth,” Koch concluded.
Second Quarter 2026 Consolidated Results(1)
Dollars in millions, except EPS
Change
vs. 2Q’25
Organic Sales (2)
vs. 2Q’25
Net sales$1,819$1,7494%4%
GAAP Income from continuing operations$191$24n.m.
Operating EBITDA(2) $448$4236%
Operating EBITDA margin(2) % 24.6%24.2%40 bps
GAAP EPS from continuing operations$1.37$0.17n.m.
Adjusted EPS(2) $1.88$1.2748%
Cash provided by operating activities – cont. ops.$400$74n.m.
Transaction-adjusted free cash flow(2)
$326$107205%
(1)Results and cash flows are presented on a continuing operations basis. See page 6 for further information, including the basis of presentation included in this release.
(2)Organic sales, operating EBITDA, operating EBITDA margin, adjusted EPS, transaction-adjusted free cash flow and transaction-adjusted free cash flow conversion are non-GAAP measures and only reflect continuing operations. See page 6 for further discussion, including a definition of significant items. Reconciliation to the most directly comparable GAAP measure, including details of significant items begins on page 13 of this communication.
Net sales
•Net sales were up 4% on a 4% increase in organic sales.
• 4% organic sales growth in Healthcare & Water Technologies; 3% organic sales growth in Diversified Industrials.
GAAP Income from continuing operations
•GAAP Income/GAAP EPS from continuing operations improved on higher segment earnings and lower interest expense and transaction costs.
Operating EBITDA
•Operating EBITDA increased on organic growth and productivity.
Adjusted EPS
•Adjusted EPS increased on higher segment earnings, lower net interest expense and a lower tax rate.
Cash provided by operating activities from continuing operations
•Cash provided by operating activities from continuing operations in the quarter of $400 million, capital expenditures of $76 million and separation-related transaction costs and other payments of $2 million resulted in transaction-adjusted free cash flow and related conversion of $326 million and 127%, respectively.
Second Quarter 2026 Segment Highlights
Healthcare & Water Technologies
Dollars in millions
Change
vs. 2Q’25
Organic Sales(2)
vs. 2Q’25
Net sales$856$8175%4%
Operating EBITDA$258$2484%
Operating EBITDA margin %30.1%30.4%(30) bps
Net sales
•Net sales increased 5% on organic sales growth of 4% and a currency benefit of 1%.
◦Healthcare Technologies sales up mid-single digits on an organic basis on broad-based growth led by personal protection and biopharma.
◦Water Technologies sales up low-single digits on an organic basis on continued strength in industrial water and semiconductor markets, partially offset by weakness in the Middle East.
Operating EBITDA
•Operating EBITDA increased on organic growth and productivity, partially offset by growth investments.
• Operating EBITDA margin of 30.1% decreased 30 basis points as organic growth and productivity were more than offset by less favorable mix and growth investments.
2
Diversified Industrials
Dollars in millions
2Q’25Change vs. 2Q’25 Organic Sales(2)
vs. 2Q’25
Net sales$963$9323%3%
Operating EBITDA$213$1997%
Operating EBITDA margin %22.1%21.4%70 bps
Net sales
•Net sales increased 3% on organic sales growth i
May 5, 2026 · 100% conf.
1D
+1.52%
$49.98
Act: +1.69%
5D
+2.68%
$50.55
Act: +2.66%
20D
+1.35%
$49.89
Act: -2.54%
2 exhibit991enrschedules-1q26.htm
Document
Exhibit 99.1
DuPont Reports First Quarter 2026 Results
Exceeds First Quarter 2026 Guidance
Raises Full Year 2026 Guidance
First Quarter 2026 Highlights
•Net Sales of $1.7 billion increased 4%; organic sales increased 2% versus year-ago period
•GAAP Income from continuing operations of $150 million; operating EBITDA of $414 million
• GAAP EPS from continuing operations of $0.36; adjusted EPS of $0.55
• Cash provided by operating activities from continuing operations of $232 million; transaction-adjusted free cash flow of $147 million
• Completed the previously announced divestiture of the Aramids business on April 1st
• Announces $275 million accelerated share repurchase expected to be launched imminently
WILMINGTON, Del., May 5, 2026 - DuPont (NYSE: DD) announced its financial results(1) for the first quarter ended March 31, 2026 and raised financial guidance for the full year 2026.
“We delivered a strong start to the year, exceeding our financial guidance through disciplined commercial and operational execution” said Lori Koch, DuPont Chief Executive Officer. “Our teams remained focused on our customers and delivered organic growth, margin expansion, and double-digit adjusted EPS growth, along with solid cash flow generation in the quarter.”
“Our strategic priorities are clear and we remain focused on value creation by serving our customers, driving commercial and operational excellence and allocating capital thoughtfully to deliver consistent performance to our shareholders,” Koch concluded.
First Quarter 2026 Consolidated Results(1)
Dollars in millions, except EPS
Change
vs. 1Q’25
Organic Sales (2)
vs. 1Q’25
Net sales$1,681$1,6124%2%
GAAP Income from continuing operations$150$8088%
Operating EBITDA(2) $414$36015%
Operating EBITDA margin(2) % 24.6%22.3%230 bps
GAAP EPS from continuing operations$0.36$0.1989%
Adjusted EPS(2) $0.55$0.3653%
Cash provided by operating activities – cont. ops.$232$77201%
Transaction-adjusted free cash flow(2)
$147$8n.m
(1)Results and cash flows are presented on a continuing operations basis. See page 6 for further information, including the basis of presentation included in this release.
(2)Organic sales, operating EBITDA, operating EBITDA margin, adjusted EPS, transaction-adjusted free cash flow and transaction-adjusted free cash flow conversion are non-GAAP measures and only reflect continuing operations. See page 6 for further discussion, including a definition of significant items. Reconciliation to the most directly comparable GAAP measure, including details of significant items begins on page 13 of this communication.
Net sales
•Net sales were up 4% on a 2% increase in organic sales and a 2% currency benefit.
• 3% organic sales growth in Healthcare & Water Technologies; about flat organic sales growth in Diversified Industrials.
GAAP Income from continuing operations
•GAAP Income/GAAP EPS from continuing operations improved on higher segment earnings and lower interest expense, partially offset by the absence of a prior year gain on interest rate swaps.
Operating EBITDA
•Operating EBITDA increased on organic growth, favorable mix and productivity.
Adjusted EPS
•Adjusted EPS increased on higher segment earnings and lower interest expense, corporate costs and tax rate.
Cash provided by operating activities from continuing operations
•Cash provided by operating activities from continuing operations in the quarter of $232 million, capital expenditures of $102 million and separation-related transaction costs and other payments of $17 million resulted in transaction-adjusted free cash flow and related conversion of $147 million and 65%, respectively.
First Quarter 2026 Segment Highlights
Healthcare & Water Technologies
Dollars in millions
Change
vs. 1Q’25
Organic Sales(2)
vs. 1Q’25
Net sales$806$7636%3%
Operating EBITDA$244$2239%
Operating EBITDA margin %30.3%29.2%110 bps
Net sales
•Net sales increased 6% on organic sales growth of 3% and a currency benefit of 3%.
◦Healthcare Technologies sales up high-single digits on an organic basis on broad-based growth led by medical packaging and biopharma.
◦Water Technologies sales down low to mid-single digits on an organic basis as strength in industrial water and microelectronics markets were more than offset by logistics disruptions in the Middle East.
Operating EBITDA
•Operating EBITDA increased on organic growth and productivity.
• Operating EBITDA margin of 30.3% increased 110 basis points on organic growth, favorable mix and productivity.
2
Diversified Industrials
Dollars in millions
1Q’25Change vs. 1Q’25 Organic Sales(2)
vs. 1Q’25
Net sales$875$8493%~flat
Operating EBITDA$200$1858%
Operating EBITDA margin %22.9%21.8%110 bps
Net sales
•Net sales increased 3% on a currency benefit of 3%. Organic sales were about flat in the quarter.
◦Building Technologies sale
This page provides DuPont de Nemours Inc. (DD) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on DD's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.